Status:
UNKNOWN
Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
Myelofibrosis, Primary
Myelofibrosis, Post PV
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of the study is to determine the rate of HMR mutations in PMF and secondary MF (post PV/ET) subjects, and correlate the rate of mutations with clinical features as known prognostic scores.
Detailed Description
Main inclusion criteria: 1. Diagnosis of PMF, post PV MF or post ET MF according to the WHO 2008 classification 2. Age ≥ 18 years 3. Concurrent participation in clinical trials will be allowed. Effi...
Eligibility Criteria
Inclusion
- Diagnosis of PMF, post PV MF or post ET MF according to the WHO 2008 classification
- Age . 18 years
- Patient is willing and capable of giving a written informed consent.
- Concurrent participation in clinical trials will be allowed
Exclusion
- Unwilling or unable to provide informed consent
- Prefibrotic MF
Key Trial Info
Start Date :
December 10 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 9 2020
Estimated Enrollment :
222 Patients enrolled
Trial Details
Trial ID
NCT03402399
Start Date
December 10 2017
End Date
December 9 2020
Last Update
July 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assaf Harofeh Medical Center
Ẕerifin, Israel